Intended Audience
This complimentary CME educational activity is designed for all oncologists, surgical oncologists, radiologists, oncology nurses, and other health care professionals managing patients with metastatic breast cancer.

Program Medium
Internet-based program

Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period January 25, 2013 through January 25, 2015 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 101 segments totaling 3.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate

Estimated Time to Complete Educational Activity
3.5 hours

Course Overview
In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances the management of metastatic breast cancer.

Release Date
January 25, 2013

Expiration Date
January 25, 2015

Registration
Participation in this iQ&A interactive Medical Intelligence Zone for Metastatic Breast Cancer is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support
Supported by an educational grant from Eisai, Inc.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Complete Conference Management and CMEducation Resources, LLC. Complete Conference Management is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement
Complete Conference Management designates this enduring material for a maximum of 3.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure
It is the policy of Complete Conference Management to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by Complete Conference Management are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty and Disclosure

Ricardo Alvarez, MD, MSc
Assistant Professor
Department of Breast Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Assistant Professor, The Morgan Welch Inflammatory
Breast Cancer Research Program and Clinic
Houston, Texas

Nothing to disclose

Stefan Gl?ck, MD, PhD
Professor of Medicine
Miller School of Medicine
University of Miami
Clinical Director, Braman Family Breast Cancer Institute
Sylvester Comprehensive Cancer Center

Research Support: Amgen, Agendia, Celgene, GSK, GHI, Eisai
Consultant/Advisory Board: Amgen, Agendia, Celgene, GSK, GHI, Eisai

William J. Gradishar, MD
Professor of Medicine
Division of Hematology and Medical Oncology
Feinberg School of Medicine at Northwestern University
Director of Breast Medical Oncology
Associate Director, Lynn Sage Comprehensive Breast Program
Chicago, Illinois

Research Support: Eisai

Peter A. Kaufman, MD
Associate Professor of Medicine
Department of Medical Oncology and Hematology
Dartmouth Medical School
Norris Cotton Cancer Center
Lebanon, New Hampshire

Research Support: Genentech
Consultant: Genentech

Virginia Kaklamani, MD
Associate Professor
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Research Support: Eisai
Speaker Honoraria: Celgene, Genentech
Advisory Board: Celgene, Genentech

Minetta Liu, MD
Assistant Professor, Division of Hematology/Oncology
Department of Medicine
Lombardi Comprehensive Cancer Center
Mayo Clinic
Rochester, MD

Research Support: Eisai

Susan L. Mooberry, PhD
Professor of Pharmacology
Co-leader of Experimental and Developmental Therapeutics
Cancer Therapy and Research Center
University of Texas Health Science Center at San Antonio
University of Texas
San Antonio, Texas

Research Grant: Remeditex Ventures
Advisory Board: Eisai

Joyce O'Shaughnessy, MD
Baylor-Sammons Cancer Center in Dallas
Co-Chair, Breast Cancer Research
Chair, Cancer Prevention Research
U.S. Oncology Clinical Trials Network
Houston, Texas

Honorarium: Abraxis BioScience, AstraZeneca, Genentech BioOncology, GlaxoSmithKline, sanofi-aventis Group

Edith Perez, MD
Professor of Medicine
Mayo Medical School
Director of the Breast Program
Chair of the Cancer Clinical Study Unit
Mayo Clinic, Florida

Grant/Research Support: Sanofi Oncology, Genentech, GSK

Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Speaker's Bureau: Genomic Health
Grant/Research Support: Abbott, BMS, GSK, Genentech, Novartis, Merck, Sanofi- Aventis

Lee S. Schwartzberg, MD FACP
Medical Director, The West Clinic
Clinical Professor of Medicine
University of Tennessee College of Medicine
Memphis, Tennessee

Grant/Research Support: Eisai, BMS
Speaker Honoraria: Eisai

Katherine H. Rak Tkaczuk, MD
Professor of Medicine and Oncology
Director, Breast Evaluation and Treatment Program
Medical Oncologist?
University of Maryland Medical Center
Baltimore, Maryland

Nothing to disclose

Tiffany A. Traina, MD
Assistant Professor
Weill Medical College of Cornell University
Assistant Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Research Support: Eisai
Speaker/Honoraria: Eisai
Advisory Board: Genentech

Debu Tripathy, MD
Professor of Medicine
Priscilla and Art Ulene Chair in Women’s Cancer
Co-Leader, Women's Cancer Program
University of Southern California
Los Angeles, California

Nothing to disclose

Professor Christopher Twelves, MD
NTRAC Professor of Clinical Cancer Pharmacology and Oncology
Professor and Honorary Consultant in Medical Oncology
St. James's University Hospital
Leeds, United Kingdom

Speaker's Bureau: Roche, Eisai
Advisory Board: Eisai

Linda Vahdat MD
Professor of Medicine
Director, Breast Cancer Research Program
Head, Solid Tumor Service
Weill Cornell Medical College
New York, New York

Research Support: Eisai
Speaker Honoraria: Eisai, Bristol-Myers Squibb

Amelia Zelnak, MD, MSc
Assistant Professor of Hematology and Oncology
Winship Cancer Institute
Emory University Sc

Research Support: Eisai, Bayer

Program Managers and Web Editor Disclosure
Program Manager Gideon Bosker, MD has nothing to disclose.
Program Manager Sarah Gray, MD has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will:

• Implement strategies to improve survival in patients with metastatic breast cancer (MBC) who have received one, two, or three established chemotherapeutic treatment courses with documented remissions
• Describe strategies to improve overall survival in patients with MBC, and sequencing of agents—timing of initiation and combinations—to improve outcomes
• Implement ASCO and NCCN Guidelines for management of patients with advanced and metastatic breast cancer
• Understand the safety, efficacy, and survival prolongation profiles associated with novel treatments being evaluated for MSB, including the role of nontaxane, microtubule dynamics inhibitors
• Detail the tolerability, outcomes, and evidence-based rationale for the use of microtubule inhibitors in heavily pretreated women with metastatic breast cancer who had already received treatment with anthracycline and a taxane for MBC

Disclaimer

Copyright © 2013 by CMEducation Resources, LLC All rights reserved. 

Reproduction, distribution, or translation without express written permission is strictly prohibited. 

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity. 

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations. 

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman. 

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © CMEducation Resources, LLC